Murtala Muhammed Specialist Hospital Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2016
NCT02560935
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

hydroxyurea (hydrea) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 3)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1